ABBV vs AMGN: fair value comparison
AbbVie Inc. and Amgen Inc. · Updated 2026-09-13
ABBV currently screens as fairly valued while AMGN screens as overvalued. Within Healthcare, ABBV currently sits closer to the top of our discount ranking.
| ABBV | AMGN | |
|---|---|---|
| Verdict | Fairly valued | Overvalued |
| Last price | $257.12 | $377.35 |
| 12-month range | $205.15–$259.99 | $288.34–$438.12 |
| Sector rank | #86 of 113 Healthcare | #91 of 113 Healthcare |
| Quality grade | B | B |
| Leverage | Low | High |
| Margin trend | Stable | Expanding |
| Revenue growth | Modest | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Mixed |
| DCF cross-check | Undervalued | Undervalued |
| 52-week position | The top quarter | The upper-middle quarter |
Full single-stock breakdowns: ABBV fair value analysis · AMGN fair value analysis